

## **Long term follow-up using digital linkage of patients participating in the RAPID trial: Patient notification - November 2023**

Since the publication of initial results of the RAPID trial in 2015 a further 8 years has elapsed and we want to know if survival still remains the same in both arms of the trial. We'd also like to find out if there's any difference in the incidence of second cancers and heart disease between patients receiving chemotherapy alone and those receiving chemotherapy plus radiotherapy. This is important for future patients and their doctors as they make decisions about treatment.

Follow-up information is usually provided by the hospital where treatment was given but in most cases patients participating in the RAPID trial have now been discharged. For this reason we asked the Confidentiality Advisory Group (CAG) for permission to obtain follow-up information through a linkage with NHS England and the National Institute for Cardiovascular Outcomes Research (NICOR). This linkage has been allowed by CAG using the provisions of Section 251 but RAPID trial participants may opt-out of this mode of follow-up by contacting the Christie NHS Foundation Trust (trial sponsor) sponsorship team ([the-christie.sponsoredresearch@nhs.net](mailto:the-christie.sponsoredresearch@nhs.net)).

Professor John Radford, Chief Investigator of RAPID trial